Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.

Abstract excerpt

INTRODUCTION: Despite treatment strategies which include both surgery and chemotherapy, epithelial ovarian cancer often relapses and survival rates remain poor. There is therefore a need to identify novel treatment targets and develop approaches that improve outcomes. The role of both germ line and somatic mutations in BRCA1 and BRCA2 in the development of ovarian cancer is well established, with mutation in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to BRCA1 Protein
• Share to BRCA2 Protein
• Share to Carcinoma, Ovarian Epithelial